Endocrine Function in 97 Patients with Myotonic Dystrophy Type 1

Overview

Journal J Neurol

Specialty Neurology

Date 2012 Feb 22

PMID 22349862

Citations 18

Authors

M C Orngreen

P Arlien-Soborg

M Duno

J M Hertz

J Vissing

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to investigate the endocrine function and its association to number of CTG repeats in patients with myotonic dystrophy type 1 (DM1). Concentration of various hormones and metabolites in venous blood was used to assess the endocrine function in 97 patients with DM1. Correlation with CTG(n) expansion size was investigated with the Pearson correlation test. Eighteen percent of the DM1 patients had hyperparathyroidism with increased PTH compared with 0.5% in the background population. Of these, 16% had normocalcemia and 2% had hypercalcemia. An additional 3% had hypercalcemia without elevation of PTH; 7% had abnormal TSH values (2% subnormal and 5% elevated TSH levels); 5% of the patients had type 2 diabetes mellitus; 17% of the male DM1 patients had increased LH and low levels of plasma testosterone indicating absolute androgen insufficiency. Another 21% had increased LH, but normal testosterone levels, indicating relative insufficiency. Numbers of CTG repeats correlated directly with plasma PTH, phosphate, LH, and tended to correlate with plasma testosterone for males. This is the largest study of endocrine dysfunction in a cohort of Caucasian patients with DM1. We found that patients with DM1 have an increased risk of abnormal endocrine function, particularly calcium metabolism disorders. However, the endocrine dysfunction appears not to be of clinical significance in all of the cases. Finally, we found correlations between CTG(n) expansion size and plasma PTH, phosphate, and testosterone, and neck flexion strength.

Citing Articles

A case of early onset diabetes with myotonic dystrophy type 1.

Wan J, Zhao L, Jin P Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023; 48(6):930-934.

PMID: 37587079 PMC: 10930443. DOI: 10.11817/j.issn.1672-7347.2023.220599.

Energy Expenditure, Body Composition, and Skeletal Muscle Oxidative Capacity in Patients with Myotonic Dystrophy Type 1.

Joosten I, Fuchs C, Beelen M, Plasqui G, van Loon L, Faber C J Neuromuscul Dis. 2023; 10(4):701-712.

PMID: 37154183 PMC: 10357167. DOI: 10.3233/JND-230036.

Targeting Myotonic Dystrophy Type 1 with Metformin.

Garcia-Puga M, Saenz-Antonanzas A, Matheu A, de Munain A Int J Mol Sci. 2022; 23(5).

PMID: 35270043 PMC: 8910924. DOI: 10.3390/ijms23052901.

Transcriptional signatures of synaptic vesicle genes define myotonic dystrophy type I neurodegeneration.

Jimenez-Marin A, Diez I, Labayru G, Sistiaga A, Caballero M, Andres-Benito P Neuropathol Appl Neurobiol. 2021; 47(7):1092-1108.

PMID: 33955002 PMC: 9292638. DOI: 10.1111/nan.12725.

Multisystemic Impairments in 93 Chinese Patients With Myotonic Dystrophy Type 1.

Li M, Wang Z, Cui F, Yang F, Wang H, Huang X Front Neurol. 2020; 11:277.

PMID: 32373051 PMC: 7186325. DOI: 10.3389/fneur.2020.00277.

References

Moxley 3rd R, Logigian E, Martens W, Annis C, Pandya S, Moxley 4th R . Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonic dystrophy (DM1). Muscle Nerve. 2007; 36(3):320-8. DOI: 10.1002/mus.20822. View

Martorell L, Martinez J, Carey N, Johnson K, Baiget M . Comparison of CTG repeat length expansion and clinical progression of myotonic dystrophy over a five year period. J Med Genet. 1995; 32(8):593-6. PMC: 1051631. DOI: 10.1136/jmg.32.8.593. View

Miller S, Dykes D, Polesky H . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3):1215. PMC: 334765. DOI: 10.1093/nar/16.3.1215. View

Marchini C, Lonigro R, Verriello L, Pellizzari L, Bergonzi P, Damante G . Correlations between individual clinical manifestations and CTG repeat amplification in myotonic dystrophy. Clin Genet. 2000; 57(1):74-82. DOI: 10.1034/j.1399-0004.2000.570112.x. View

Nakamura A, Kojo T, Arahata K, Takeda S . Reduction of serum IgG level and peripheral T-cell counts are correlated with CTG repeat lengths in myotonic dystrophy patients. Neuromuscul Disord. 1996; 6(3):203-10. DOI: 10.1016/0960-8966(96)00010-7. View

Brook J, McCurrach M, Harley H, Buckler A, Church D, Aburatani H . Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell. 1992; 68(4):799-808. DOI: 10.1016/0092-8674(92)90154-5. View

Kinoshita M, Komori T, Ohtake T, Takahashi R, Nagasawa R, Hirose K . Abnormal calcium metabolism in myotonic dystrophy as shown by the Ellsworth-Howard test and its relation to CTG triplet repeat length. J Neurol. 1997; 244(10):613-22. DOI: 10.1007/s004150050155. View

Yoshida H, Oshima H, Saito E, Kinoshita M . Hyperparathyroidism in patients with myotonic dystrophy. J Clin Endocrinol Metab. 1988; 67(3):488-92. DOI: 10.1210/jcem-67-3-488. View

Laurberg P, Pedersen K, Hreidarsson A, Sigfusson N, Iversen E, Knudsen P . Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark. J Clin Endocrinol Metab. 1998; 83(3):765-9. DOI: 10.1210/jcem.83.3.4624. View

10.

Carstensen B, Kristensen J, Ottosen P, Borch-Johnsen K . The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia. 2008; 51(12):2187-96. DOI: 10.1007/s00125-008-1156-z. View

11.

Machuca-Tzili L, Brook D, Hilton-Jones D . Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve. 2005; 32(1):1-18. DOI: 10.1002/mus.20301. View

12.

Baghernajad Salehi L, Bonifazi E, Di Stasio E, Gennarelli M, Botta A, Vallo L . Risk prediction for clinical phenotype in myotonic dystrophy type 1: data from 2,650 patients. Genet Test. 2007; 11(1):84-90. DOI: 10.1089/gte.2006.0511. View

13.

Lee F, Hughes D . SYSTEMIC EFFECTS IN DYSTROPHIA MYOTONICA. Brain. 1964; 87:521-36. DOI: 10.1093/brain/87.3.521. View

14.

Klein A, Gasnier E, Furling D . Gain of RNA function in pathological cases: Focus on myotonic dystrophy. Biochimie. 2011; 93(11):2006-12. DOI: 10.1016/j.biochi.2011.06.028. View

15.

Savkur R, Philips A, Cooper T . Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet. 2001; 29(1):40-7. DOI: 10.1038/ng704. View

16.

Annane D, Duboc D, Mazoyer B, Merlet P, Fiorelli M, Eymard B . Correlation between decreased myocardial glucose phosphorylation and the DNA mutation size in myotonic dystrophy. Circulation. 1994; 90(6):2629-34. DOI: 10.1161/01.cir.90.6.2629. View

17.

Clarke N, Kelion A, Nixon J, Hilton-Jones D, Forfar J . Does cytosine-thymine-guanine (CTG) expansion size predict cardiac events and electrocardiographic progression in myotonic dystrophy?. Heart. 2001; 86(4):411-6. PMC: 1729946. DOI: 10.1136/heart.86.4.411. View

18.

Morrone A, Pegoraro E, Angelini C, Zammarchi E, Marconi G, Hoffman E . RNA metabolism in myotonic dystrophy: patient muscle shows decreased insulin receptor RNA and protein consistent with abnormal insulin resistance. J Clin Invest. 1997; 99(7):1691-8. PMC: 507989. DOI: 10.1172/JCI119332. View

19.

Griggs R, Kingston W, Jozefowicz R, Herr B, Forbes G, Halliday D . Effect of testosterone on muscle mass and muscle protein synthesis. J Appl Physiol (1985). 1989; 66(1):498-503. DOI: 10.1152/jappl.1989.66.1.498. View

20.

Okuno T, Mori K, Furomi K, Takeoka T, Kondo K . Myotonic dystrophy and hyperthyroidism. Neurology. 1981; 31(1):91-3. DOI: 10.1212/wnl.31.1.91. View